BRAF and non-small cell lung carcinoma: Promising efficacy and safety have been demonstrated with BRAF inhibitors, such as dabrafenib (Planchard K. et al., 2016), vemurafenib (Subbiah et al., 2019), and the combination of dabrafenib plus trametinib (Planchard B. et al., 2016; Planchard et al., 2017; Ettinger et al., 2021), in clinical trials involving advanced BRAF V600E mutant NSCLC.